Cytokinetics (CYTK) Cash from Operations (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Cash from Operations of 145500000.0 for Q1 2026, down 10.55% year-over-year from 162657121.14 in Q1 2025, and down 2.0% quarter-over-quarter from 142642000.0 in Q4 2025.
Powered by 
Analysis
Cytokinetics (CYTK) Cash from Operations (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Cash from Operations for 17 consecutive years, with 145500000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 10.55% year-over-year to 145500000.0; the TTM figure through Mar 2026 stood at 523883000.0 (down 31.63% YoY), while the FY2025 annual figure was 510000000.0, down 28.82% from the prior year.
- Cash from Operations eased to 145500000.0 in Q1 2026 per CYTK's latest filing, from 142642000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 26811000.0 in Q1 2022 and bottomed at 145500000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 103837588.24 across 5 years, with a median of 101500000.0 in 2024.
- On a YoY basis, Cash from Operations climbed as much as 24.6% in 2023 and fell as far as 356.1% in 2023.
- Cytokinetics' Cash from Operations stood at 98190000.0 in 2022, then climbed by 24.6% to 74037000.0 in 2023, then climbed by 11.44% to 65570000.0 in 2024, then slumped by 117.54% to 142642000.0 in 2025, then slipped by 2.0% to 145500000.0 in 2026.
- Business Quant data shows CYTK's Cash from Operations at 145500000.0 in Q1 2026, 142642000.0 in Q4 2025, and 107505000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Cytokinetics | 9.63 Bn | 8.46 Bn | 25.89 Mn | -159.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -159.80 Mn |
| Mar 31, 2026 | -145.50 Mn |
| Dec 31, 2025 | -142.61 Mn |
| Sep 30, 2025 | -107.55 Mn |
| Jun 30, 2025 | -128.24 Mn |
| Mar 31, 2025 | -131.62 Mn |
| Dec 31, 2024 | -65.57 Mn |
| Sep 30, 2024 | -101.50 Mn |
| Jun 30, 2024 | -99.31 Mn |
| Mar 31, 2024 | -129.51 Mn |
| Dec 31, 2023 | -74.04 Mn |
| Sep 30, 2023 | -96.21 Mn |
| Jun 30, 2023 | -121.81 Mn |
| Mar 31, 2023 | -122.29 Mn |
| Dec 31, 2022 | -98.19 Mn |
| Sep 30, 2022 | -84.04 Mn |
| Jun 30, 2022 | -90.48 Mn |
| Mar 31, 2022 | -26.81 Mn |
| Dec 31, 2021 | -44.74 Mn |
| Sep 30, 2021 | -38.77 Mn |